Clinical Trials Logo

Clinical Trial Summary

Intrauterine growth restriction (IUGR) is caused when the placenta cannot provide enough nutrients to allow normal growth of the fetus during pregnancy. It is unclear why IUGR happens, but an increase in inflammatory T cells in the placenta known as villitis of unknown etiology (VUE) is observed in many IUGR infants. The investigators aim to develop ultrasound methods for diagnosing VUE to understand it's role in IUGR.


Clinical Trial Description

Intrauterine growth restriction (IUGR) occurs in 3-10% of all pregnancies and is associated with significant morbidity and mortality during pregnancy, after birth and throughout the child's lifespan. IUGR is caused by the inability of the placental vasculature to provide enough oxygen and nutrients to support the fetus; yet, the mechanisms leading to disruption of placental vasculature are unknown. The placenta of ~50% of IUGR fetuses are infiltrated with inflammatory cells, specifically maternal T cells, which destroy placental blood vessels that support the fetus. This infiltration of T cells is known as villitis of unknown etiology (VUE). The diagnosis of VUE is problematic because it occurs without clinical signs and symptoms of maternal (or fetal) distress and puts the fetus at significant risk of demise. Additionally, VUE commonly recurs in subsequent pregnancies putting future offspring at risk. Yet, the exact prevalence of VUE and its significance in IUGR pathogenesis and outcomes are poorly understood as VUE is only diagnosed after the infant is outside the womb. Therefore, the study aims to recognize risk factors and cellular mechanisms associated with VUE and develop methods for diagnosing and treating VUE in utero, in order to improve infant health. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04506970
Study type Observational
Source Mayo Clinic
Contact
Status Completed
Phase
Start date September 27, 2020
Completion date October 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03866863 - Intra Uterine Growth Restriction
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Not yet recruiting NCT05720169 - Fetal, Obstetrics and Reproduction Genomics
Completed NCT04633551 - Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes N/A
Recruiting NCT05500989 - PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
Recruiting NCT04141189 - Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation N/A
Completed NCT03726697 - Effect of Tahneek on Hypoglycemia in Newborn Infants N/A
Recruiting NCT03398629 - Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies
Recruiting NCT02473991 - Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight N/A
Completed NCT02696577 - The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction Phase 2
Recruiting NCT04766866 - sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term. N/A
Terminated NCT04047966 - Study of the Fetal and Maternal Microbiota in Preganant Women With Fetal Defect Growth
Not yet recruiting NCT03865628 - Ultrasound Evaluation of Fetal Hemodynamics and Perinatal Complications
Completed NCT05328453 - Sonographic 3D Measurement of Fetal Thymus May be Used to Predict the Small Baby in Pregnancy.
Completed NCT05800938 - The Effect of Oral Isosorbide Mononitrate Therapy on Umbilical Artery Doppler Resistance Index in Pregnancies With Intrauterine Growth Restriction: Prospective Randomized Control Trial Phase 4
Not yet recruiting NCT06226051 - Growing Little PEAPODS Study
Recruiting NCT02807324 - Women Specific Cardiac Recovery After Preeclampsia
Recruiting NCT02515292 - Evaluation of Infants With Intrauterine Growth Restriction N/A
Active, not recruiting NCT01942525 - Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants N/A
Withdrawn NCT04557475 - Transplacental Aspirin Therapy for Early Onset Fetal Growth Restriction Phase 3